نتائج البحث - "Edvard Zhavrid"

1

دورية أكاديمية

Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial

المؤلفون: Dilyara Kaidarova, Edvard Zhavrid, Oxana Shatkovskaya, Aliaksandr Prokharau, Nina Akhmed, Dauren Sembayev, Zhanna Rutzhanova, Alexandr Ivankov

المصدر: Cancer Treatment and Research Communications, Vol 40, Iss , Pp 100817- (2024)

مصطلحات موضوعية: Subcutaneous injection, Intravenous injection, Trastuzumab, Breast cancer, Randomized control trial, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2468294224000297Test; https://doaj.org/toc/2468-2942Test

الوصول الحر: https://doaj.org/article/9bfed06629a640149cf386d3975e418fTest

View record in DOAJ

النص الكامل

2

Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study

المصدر: Clinical Lymphoma Myeloma & Leukemia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20ac8f612d136062b207eac5743a8146Test
https://doi.org/10.1016/j.clml.2021.08.005Test

3

دورية أكاديمية

Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial ... : فعالية وسلامة CT - P6 مقابل التراستوزوماب المرجعي في سرطان الثدي المبكر HER2 الإيجابي: نتائج محدثة لتجربة المرحلة 3 العشوائية ...

المؤلفون: Francisco J. Esteva, Y. Baranau, V. Baryash, A. Manikhas, Vladimir Moiseyenko, Giorgi Dzagnidze, Edvard Zhavrid, Dmytro Boliukh, Daniil Stroyakovskiy, Joanna Pikiel, Alexandru Eniu, R. K. Li, Andriy Rusyn, B. Tiangco, S. J. Lee, S. Young Lee, Sunyoung Yu, Justin Stebbing

مصطلحات موضوعية: HER2 Signaling in Breast Cancer Treatment, Oncology, Medicine, Health Sciences, Therapeutic Antibodies Development, Engineering, and Applications, Radiology, Nuclear Medicine and Imaging, Development and Applications of Radiopharmaceuticals, Trastuzumab, Breast Cancer, Breast cancer, Internal medicine, Adjuvant, Adverse effect, Biosimilar, Clinical trial, Stage stratigraphy, Cancer, Paleontology, Biology

العلاقة: https://dx.doi.org/10.60692/xwv74-fvh58Test

الإتاحة: https://doi.org/10.60692/z6d6z-tbb7110.60692/xwv74-fvh58Test

View record in BASE

4

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study

المؤلفون: KeumYoung Ahn, Mariana Vasilica, Christian Buske, Rajnish Nagarkar, Edvard Zhavrid, Aliaksandr Prokharau, Sung-Hyun Kim, Juan-Manuel Sancho, Michinori Ogura, Won Seog Kim, Wojciech Jurczak, Jose Angel Hernandez-Rivas, Jin Seok Kim, Sang Joon Lee, Larry W. Kwak

المصدر: Blood Adv

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::570156d56cfdcfb078330f5d56b56710Test
https://doi.org/10.1182/bloodadvances.2021004484Test

5

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)

المؤلفون: Istvan Abert, Avana Investigators, Dongyue Fu, Z. Andric, Igor Bondarenko, Kristina Galić, Zahid Bashir, Konstantinos N. Syrigos, Vladimer Kuchava, Rinat Galiulin, D. Trukhin, Stephanie Jones, Mikhail Dvorkin, Laurent M Kassalow, Virote Sriuranpong, Edvard Zhavrid

المصدر: Biodrugs

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::862ff42a47137180ff1d26248dac3bdcTest
https://doi.org/10.1007/s40259-021-00489-4Test

6

Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial

المؤلفون: Giorgi Dzagnidze, Justin Stebbing, Alexey Manikhas, Alexandru Eniu, Rubi K. Li, V. Baryash, Edvard Zhavrid, Joanna Pikiel, Vladimir Moiseyenko, Dmytro Boliukh, Yauheni Valerievich Baranau, Sang Joon Lee, Sunghyun Kim, Beatrice Tiangco

المساهمون: National Institute for Health Research, Imperial College Healthcare NHS Trust- BRC Funding

المصدر: Breast Cancer Research and Treatment

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, Receptor, ErbB-2, medicine.medical_treatment, MULTICENTER, THERAPY, Ventricular Function, Left, 0302 clinical medicine, Trastuzumab, CYCLOPHOSPHAMIDE, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, skin and connective tissue diseases, Neoadjuvant therapy, ADJUVANT TRASTUZUMAB, DOCETAXEL, education.field_of_study, OUTCOMES, Biosimilar, HER2-positive early breast cancer, Hazard ratio, ASSOCIATION, OPEN-LABEL, Clinical Trial, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, SURVIVAL, Female, Life Sciences & Biomedicine, medicine.drug, medicine.medical_specialty, Population, Breast Neoplasms, Adjuvant therapy, 03 medical and health sciences, Breast cancer, Internal medicine, medicine, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, education, CT-P6, Biosimilar Pharmaceuticals, Chemotherapy, Science & Technology, business.industry, 1103 Clinical Sciences, Stroke Volume, medicine.disease, 030104 developmental biology, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::939fd5615811f9b2d106c239194815fdTest
http://europepmc.org/articles/PMC8272708Test

7

المساهمون: Institut Català de la Salut, [Tabernero J, Alsina M] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, IOB-Quiron, Barcelona, Spain. [Shitara K, Doi T] National Cancer Center Hospital East, Chiba, Japan. [Dvorkin M] Omsk Regional Clinical Centre of Oncology, Omsk, Russia. [Mansoor W] The Christie NHS Foundation Trust, Manchester, UK, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia
Gastric Cancer

مصطلحات موضوعية: Male, Cancer Research, Pyrrolidines, Health-related quality of life, Medicaments antineoplàstics - Ús terapèutic, Trifluridine, tipiracil, Metastatic gastric cancer, chemistry.chemical_compound, Quality of life, Surgical oncology, Antineoplastic Combined Chemotherapy Protocols, Other subheadings::/therapeutic use [Other subheadings], ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida [ATENCIÓN DE SALUD], Aged, 80 and over, Trifluridine/tipiracil, Gastroenterology, General Medicine, Middle Aged, Prognosis, humanities, Survival Rate, Oncology, Estómac - Càncer, Female, Original Article, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Stomach Neoplasms [DISEASES], Life Sciences & Biomedicine, Qualitat de vida - Avaluació, medicine.drug, Adult, MODULE, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias gástricas [ENFERMEDADES], medicine.medical_specialty, Adolescent, Adenocarcinoma, Phase 3, Placebo, Young Adult, Double-Blind Method, Stomach Neoplasms, Internal medicine, Post-hoc analysis, medicine, Humans, terapéutica::protocolos clínicos::protocolos antineoplásicos::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Aged, Tipiracil, Science & Technology, Gastroenterology & Hepatology, Otros calificadores::/uso terapéutico [Otros calificadores], business.industry, International Agencies, Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life [HEALTH CARE], chemistry, Quality of Life, Gastric cancer, business, Thymine, Follow-Up Studies, Abdominal surgery